EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Michael King maintains a Buy rating on Lantern Pharma (NASDAQ:LTRN) and keeps the $11 price target unchanged.
June 26, 2023 | 6:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Michael King maintains a Buy rating on Lantern Pharma (NASDAQ:LTRN) and keeps the $11 price target unchanged.
The maintained Buy rating and unchanged price target by EF Hutton analyst Michael King indicates a positive outlook for Lantern Pharma's stock. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100